AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCY

我们研究的目的是提高无病生存率和总体 通过使用高剂量的抗肿瘤药物治疗恶性血液病患者 剂量治疗和自体干细胞移植。 它的目的是 引入旨在提高疗效和潜力的新方法， 大剂量化疗或放化疗和干细胞支持的安全性 对于正在接受难治性B细胞淋巴瘤治疗的患者， 霍奇金病和白血病。 这些创新包括使用高剂量序贯化疗， 复发性霍奇金病的治疗和钇标记的用途 抗CD20抗原的单克隆抗体作为制备的一部分 接受自体骨髓移植的患者的治疗方案 (BMT)治疗B细胞淋巴瘤 我们亦会研究可行性， 添加钇标记单克隆抗体的有效性和毒性 接受自体BMT的患者中的CD33或CD45抗原， 治疗急性髓细胞白血病和费城染色体 Ph+急性淋巴细胞白血病（ALL）。 此外，在这 项目我们将研究使用一个新的载体，腺相关病毒， 用于有效转导造血干细胞的病毒。 这 方法旨在阐明造血的模式和程度， 和免疫重建，以及复发的潜在原因， 对于接受低度恶性肿瘤治疗的患者， 淋巴瘤后的辐射和非辐射含有方案。 我们 也将研究设计用来切割杂交RNA的核酶的使用 由Ph + ALL的t（9; 22）染色体易位引起， 目的是清除白血病患者外周血干细胞 接受自体骨髓移植治疗 这些研究将测试新的方法，旨在减少主要的 复发问题，这是成功使用的最大障碍， 自体干细胞移植用于治疗恶性淋巴瘤， 何杰金氏病和急性白血病。 该项目的重点是修改 治疗恶性肿瘤残留机体负荷的预备方案， 以及开发分子方法来清除干细胞 是白血病细胞污染的产物 项目2将作为 实验项目的临床资源。

The goal of our study is to improve disease-free survival and overall survival in patients with hematologic malignancies through the use of high dose therapy and autologous stem cell grafting. It is the intent to introduce novel approaches designed to increase the efficacy and potential safety of high dose chemotherapy or chemoradiotherapy and stem cell support for patients who are undergoing treatment for refractors B cell lymphoma, Hodgkin's disease and leukemia. These innovations include using high dose sequential chemotherapy for the treatment of relapsed Hodgkin's disease and the use of yttrium labeled monoclonal antibodies to the CD20 antigen as part of the preparatory regimen for patients undergoing autologous bone marrow transplantation (BMT) for B cell lymphoma. We will also study the feasibility, effectiveness and toxicity of adding yttrium labeled monoclonal antibodies to either the CD33 or CD45 antigen in patients undergoing autologous BMT as treatment for acute myelogenous leukemia and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). In addition, in this project we will investigate the use of a nw vector, an adeno-associated virus for efficient transduction of hematopoietic stem cells. This approach is designed to elucidate the pattern and degree of hematopoietic and immune reconstitution, as well as the potential cause of relapse that occurs after autologous BMT for patients undergoing treatment for low grade lymphoma following radiation and non-radiation containing regimens. We will also study the use of a ribozyme designed to cleave the hybrid RNA that results from the t (9;22) chromosome translocation of Ph+ ALL with the goal to purge peripheral blood stem cells of leukemia in patients undergoing autologous BMT for this disorder. These studies will test novel methods designed to decrease the major problem of relapse, which is the greatest obstacle to successful use of autologous stem cell transplant for treatment of malignant lymphomas, Hodgkin's disease, and acute leukemia. The project focuses on modifying the preparatory regimen to treat the residual body burden of malignancy, a well as developing molecular methods designed to purge the stem cell product of contaminating leukemia cells. Finally, Project 2 will serve as a clinical resource for experimental Projects.